Immunostimulation by OX40 Ligand Transgenic Ewing Sarcoma Cells

Overview of attention for article published in Frontiers in oncology, October 2015

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (53rd percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

So far, Altmetric has seen 7 X posts from 6 X users, with an upper bound of 44,663 followers.

Immunostimulation by OX40 ligand transgenic Ewing sarcoma cells. Front. Oncol. (open access) https://t.co/bIzLfNgqZg

RT @FrontOncology: OX40/OX40L stimulation as a strategy to improve treatment of Ewing #sarcoma https://t.co/YTRkV56GSc #immunotherapy

RT @FrontOncology: OX40/OX40L stimulation as a strategy to improve treatment of Ewing #sarcoma https://t.co/YTRkV56GSc #immunotherapy

RT @FrontOncology: OX40/OX40L stimulation as a strategy to improve treatment of Ewing #sarcoma https://t.co/YTRkV56GSc #immunotherapy

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 3 additional X posts.